Hans Rosén, born 1960

CEO

Mr. Rosén has served as CEO of Artimplant since August 2006.

Mr. Rosén has extensive experience from marketing, sales and corporate management in the life science sector. Most recently Mr. Rosén was CEO of Vivolux AB, a drug development company within cancer therapeutics.

In 1997 Mr Rosén was assigned to build the marketing and sales department of Diffchamb AB (publ.), an international biotechnology company involved in development, manufacturing and sales of instruments and reagents for food diagnostics. In 2000 Hans Rosén was appointed CEO and in 2001 Mr. Rosén took the Company to the Stockholm Stock Exchange, O-list. In 2003 Diffchamb was acquired by Raisio, a Finnish company specialized in plant-based nutrition and in ensuring food safety. Diffchamb increased its revenue by more than 25% annually, with profit, during the six years Hans Rosén was engaged by the Company.

Mr. Rosén has also served as International Sales Manager and Marketing Manager for Chromogenix AB, formerly Kabi Diagnostica. Moreover, he is the co-founder and former CEO of Neoventa AB, the company that developed the STAN™ fetal monitoring system, today marketed by Neoventa Medical AB.

Mr. Rosén holds an MSc in Industrial Engineering and Management from Chalmers University of Technology.

Other Assignments:

Member of the Board of Vivolux AB and Ottonova AB.

Holdings in Artimplant:

70 000 Series B stock units including family members holdings.

Employee incentive call options 117 056 program 2006/2011, 110 000 program 2007/2012, 112 500 program 2008/2013, 112 500 program 2009/2014.

Lars-Johan Cederbrant, born 1971

Chief Financial Officer

Employed by Artimplant since 2005.

Mr. Cederbrant has experience in finance, management, business development and restructuring from international growth companies within the medical technology industry. He has among others been CEO of CardioBridge GmbH, CFO during the restructuring of JOMED N.V. and Management Consultant at Andersen Business Consulting.

Mr. Cederbrant studied MSc in International Business Administration at the University of Lund and at Leopold Franzen´s University of Innsbruck.

Other Assignments:

Advisory board member of Inventive Capital LLP.

Holdings in Artimplant:

89 000 Series B stock units.

Employee incentive call options 49 500 program 2005/2010, 26 223 program 2006/2011, 44 799 program 2007/2012, 40 000 program 2008/2013, 44 000 program 2009/2014.

Katrin Gisselfält, born 1969

Vice President Product Development, Ph.D.

Dr. Gisselfält has been employed by Artimplant since 1995. She is one of the key scientists behind Artelon®.

Katrin Gisselfält holds a Ph.D. degree in Polymer Chemistry, Chalmers University of Technology, Gothenburg. The primary field of research has been synthesis, characterization and processing of degradable poly(urethane urea)s and their use as biomaterials.

Holdings in Artimplant:

15 000 Series B stock units.

Employee incentive call options 49 500 program 2005/2010, 26 223 program 2006/2011, 44 799 program 2007/2012, 40 000 program 2008/2013, 44 000 program 2009/2014.

Bengt Furberg, born 1941

Vice President Medical Affairs. M.D., Ph.D., Associate Professor

Dr. Furberg has been engaged as Vice President Medical Affairs since December 21, 2006.

Dr. Furberg has a wide-ranging medical background and long experience from the industry. For more than ten years Dr. Furberg was Medical Director of GlaxoWellcome Sweden and his latest assignment was as Medical Director of Bactiguard AB. He has many years experience of international requirements for obtaining regulatory clearances within pharmaceuticals and medical devices. Moreover, Dr. Furberg has worked as a medical professional, both as head of a department of clinical physiology and as head of an occupational health centre.

Dr. Furberg has published some 40 articles, among others in sports medicine and clinical trials, an area in which he also writes educational literature. Dr. Furberg holds a Ph.D. from the University of Uppsala, Sweden.

Other assignments:

Member of the Board of InDex Pharmaceuticals AB. Senior medical advisor for Bactiguard AB and member of the scientific advisory board of LinkMed AB.

Holdings in Artimplant:

20 000 Series B stock units. No options in Artimplant.

Maria Nyström, born 1964

Production Manager

Employed by Artimplant since 2000.

Maria Nyström holds a BSc in Textile Engineering from University College of Borås, Sweden.

Holdings in Artimplant:

4 500 Series B stock units

Employee incentive call options 29 799 program 2007/2012, 20 000 program 2008/2013, 24 000 program 2009/2014.

Kauko Haapasaari, born 1958

Marketing Manager

Employed by Artimplant since 2007.

Mr Haapasaari has more than 24 years of experience in the life science business. Most recently he held the position as director of business development at Raisio Diagnostics. In the past Mr Haapasaari has mainly held marketing and sales positions at Conpharm, SP-Maskiner, Swedish Trade Council, Instrument Lambda and KabiVitrum.

Kauko Haapasaari holds a B.Sc in Chemical and Administrative Sciences.

Other Assignments:

None.

Holdings in Artimplant: